LP
PYXS icon

Longaeva Partners’s Pyxis Oncology PYXS Stock Holding History

Longaeva Partners’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$735K Hold
503,214
– – 0.03% 179
2025
Q4 		$579K Hold
503,214
– – 0.05% 109
2025
Q3 		$1.12M Buy
+503,214
New +$725K 0.16% 59

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Longaeva Partners's PYXS Position: Q1 2026 in Review

Longaeva Partners held its Pyxis Oncology (PYXS) position steady in Q1 2026 at 503,214 shares worth $735K. The position accounts for 0.03% of the portfolio, ranked #179.

Longaeva Partners first reported a position in PYXS in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.12M in Q3 2025. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

  • Longaeva Partners held 503,214 shares of Pyxis Oncology worth $735K as of Q1 2026.
  • Longaeva Partners left its Pyxis Oncology share count unchanged in Q1 2026.
  • Pyxis Oncology made up 0.03% of Longaeva Partners's portfolio in Q1 2026, its #179 holding.
  • Longaeva Partners first reported a position in Pyxis Oncology in Q3 2025 and has held it in 3 quarters since.
  • Longaeva Partners's Pyxis Oncology position peaked at $1.12M in Q3 2025.
  • 78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on Longaeva Partners's 13F filing for Q1 2026, filed 15 May 2026.